SB 2384

  • North Dakota Senate Bill
  • 68th Legislative Assembly (2023-24)
  • Introduced in Senate Feb 17, 2023
  • Passed Senate Feb 09, 2023
  • House
  • Governor

A BILL for an Act to provide for a legislative management study relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.

Votes


Actions


Apr 04, 2023

House

Second reading, failed to pass, yeas 38 nays 53

Apr 03, 2023

House

Committee Hearing 03:30

House

Reported back, do not pass, placed on calendar 7 6 1

Mar 15, 2023

House

Committee Hearing 02:30

Feb 17, 2023

House

Introduced, first reading, referred to

Feb 10, 2023

House

Received from Senate

Feb 09, 2023

Senate

Second reading, passed, yeas 25 nays 22

Senate

Reported back, do not pass, placed on calendar 6 0 0

Senate

Amendment proposed on floor

Senate

Amendment adopted

Feb 08, 2023

Senate

Committee Hearing 03:44

Feb 07, 2023

Senate

Committee Hearing 09:30

Jan 23, 2023

Senate

Introduced, first reading, referred to

Bill Text

Bill Text Versions Format
FIRST ENGROSSMENT PDF
INTRODUCED PDF

Related Documents

Document Format
Prepared by the Legislative Council staff for Senator Magrum (Marked up) PDF
Prepared by the Legislative Council staff for Senator Magrum PDF

Sources

Data on Open States is updated periodically throughout the day from the official website of the North Dakota Legislative Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.